Pegasys Side Effects

Generic Name: peginterferon alfa-2a

Please note - some side effects for Pegasys may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Side Effects of Pegasys - for the Consumer

Pegasys

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome when using Pegasys:

Diarrhea; dizziness; drowsiness; dry mouth; dry or irritated skin; hair thinning; headache; loss of appetite; mild flu-like symptoms (fever, chills, muscle aches, or joint pain); nausea; pain, redness, itching, or swelling at the injection site; taste changes; temporary hair loss; tiredness; trouble sleeping; vomiting; weakness.

Seek medical attention right away if any of these SEVERE side effects occur when using Pegasys:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, throat, or tongue; unusual hoarseness); blisters or sores in the eyes, nose, or mouth; bloody or black, tarry stools; burning, numbness, or tingling in the arms, hands, legs, or feet; chest pain; confusion; coughing up yellow or pink mucus; dark urine, change in the amount of urine produced, or burning or painful urination; decreased coordination; difficulty hearing or hearing loss; eye pain or redness; fainting; fast, slow, or irregular heartbeat; new or worsening mental or mood problems (eg, anxiety, aggressive or unusual behavior, depression, hallucinations, irritability, suicidal thoughts or actions); numbness of an arm or leg; one-sided weakness; pale stools; persistent loss of appetite; persistent or severe diarrhea, nausea, stomach or back pain, or vomiting; persistent or severe fever, chills, or sore throat; red, swollen, blistered, or peeling skin; severe or unusual tiredness or weakness; slurred speech; stomach bloating; sudden leg pain; sudden, severe dizziness, headache, or vomiting; sudden shortness of breath; unusual bruising or bleeding; vision loss or other vision changes; vomit that looks like coffee grounds; weight loss; worsening psoriasis; yellowing of the eyes or skin.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

Top

Pegasys Side Effects - for the Professional

Pegasys

In clinical trials, a broad variety of serious adverse reactions were observed in 1,010 subjects who received Pegasys at doses of 180 mcg for 48 weeks, alone or in combination with COPEGUS [see Boxed Warning and Warnings and Precautions (5)]. The most common life-threatening or fatal events induced or aggravated by Pegasys and COPEGUS include depression, suicide, relapse of drug abuse/overdose, and bacterial infections, each occurring at a frequency of less than 1%. Hepatic decompensation occurred in 2% (10/574) of CHC/HIV subjects [see Warnings and Precautions (5.9)].

Clinical Trials Experience

Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug, and may not reflect the rates observed in clinical practice.

Adult Subjects

In all hepatitis C studies, one or more serious adverse reactions occurred in 10% of CHC monoinfected subjects and in 19% of CHC/HIV subjects receiving Pegasys alone or in combination with COPEGUS. The most common serious adverse reactions (3% in CHC and 5% in CHC/HIV) was bacterial infection (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia). Other SAEs occurred at a frequency of less than 1% and included: suicide, suicidal ideation, aggression, anxiety, drug abuse and drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis), peripheral neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, cerebral hemorrhage, thrombotic thrombocytopenic purpura, psychotic disorder, and hallucination.

In clinical trials, 98 to 99 percent of subjects experienced one or more adverse reactions. For hepatitis C subjects, the most commonly reported adverse reactions were psychiatric reactions, including depression, insomnia, irritability, anxiety, and flu-like symptoms such as fatigue, pyrexia, myalgia, headache, and rigors. Other common reactions were anorexia, nausea and vomiting, diarrhea, arthralgias, injection site reactions, alopecia, and pruritus. Table 8 displays pooled rates of adverse reactions occurring in greater than 5% of subjects in the Pegasys monotherapy and Pegasys/COPEGUS combination therapy clinical trials.

Overall 11% of CHC monoinfected subjects receiving 48 weeks of therapy with Pegasys either alone or in combination with COPEGUS discontinued therapy; 16% of CHC/HIV coinfected subjects discontinued therapy. The most common reasons for discontinuation of therapy were psychiatric, flu-like syndrome (e.g., lethargy, fatigue, headache), dermatologic and gastrointestinal disorders, and laboratory abnormalities (thrombocytopenia, neutropenia, and anemia).

Overall 39% of subjects with CHC or CHC/HIV required modification of Pegasys and/or COPEGUS therapy. The most common reasons for dose modification of Pegasys in CHC and CHC/HIV subjects was for neutropenia (20% and 27%, respectively) and thrombocytopenia (4% and 6%, respectively). The most common reason for dose modification of COPEGUS in CHC and CHC/HIV subjects was anemia (22% and 16%, respectively). Pegasys dose was reduced in 12% of subjects receiving 1000 mg to 1200 mg COPEGUS for 48 weeks and in 7% of subjects receiving 800 mg COPEGUS for 24 weeks. COPEGUS dose was reduced in 21% of subjects receiving 1000 mg to 1200 mg COPEGUS for 48 weeks and in 12% of subjects receiving 800 mg COPEGUS for 24 weeks.

Chronic hepatitis C monoinfected subjects treated for 24 weeks with Pegasys and 800 mg COPEGUS were observed to have lower incidence of serious adverse reactions (3% vs. 10%), Hgb less than 10 g/dL (3% vs. 15%), dose modification of Pegasys (30% vs. 36%) and COPEGUS (19% vs. 38%) and of withdrawal from treatment (5% vs. 15%) compared to subjects treated for 48 weeks with Pegasys and 1000 mg or 1200 mg COPEGUS. The overall incidence of adverse reactions appeared to be similar in the two treatment groups.

Table 8 Adverse Reactions Occurring in Greater Than or Equal to 5% of Subjects in Chronic Hepatitis C Clinical Trials (Pooled Studies 1, 2, 3, and Study 4)

	CHC Monotherapy (Pooled Studies 1-3)		CHC Combination Therapy (Study 4)
Body System	Pegasys 180 mcg 48 week*	ROFERON-A Either 3 MIU† or 6/3 MIU† of ROFERON-A 48 week*	Pegasys 180 mcg + 1000 mg or 1200 mg COPEGUS 48 week‡	Intron® A + 1000 mg or 1200 mg Rebetol ® 48 week‡
	N=559	N=554	N=451	N=443
	%	%	%	%
* Pooled studies 1, 2, and 3 † An induction dose of 6 million international units (MIU) three times a week for the first 12 weeks followed by 3 million international units three times a week for 36 weeks given subcutaneously. ‡ Study 4 § Severe hematologic abnormalities (lymphocyte less than 500 cells/mm3; hemoglobin less than 10 g/dL; neutrophil less than 750 cells/mm3; platelet less than 50,000 cells/mm3).
Application Site Disorders
Injection site reaction	22	18	23	16
Endocrine Disorders
Hypothyroidism	3	2	4	5
Flu-like Symptoms and Signs
Fatigue/Asthenia	56	57	65	68
Pyrexia	37	41	41	55
Rigors	35	44	25	37
Pain	11	12	10	9
Gastrointestinal
Nausea/Vomiting	24	33	25	29
Diarrhea	16	16	11	10
Abdominal pain	15	15	8	9
Dry mouth	6	3	4	7
Dyspepsia	<1	1	6	5
Hematologic§
Lymphopenia	3	5	14	12
Anemia	2	1	11	11
Neutropenia	21	8	27	8
Thrombocytopenia	5	2	5	<1
Metabolic and Nutritional
Anorexia	17	17	24	26
Weight decrease	4	3	10	10
Musculoskeletal, Connective Tissue and Bone
Myalgia	37	38	40	49
Arthralgia	28	29	22	23
Back pain	9	10	5	5
Neurological
Headache	54	58	43	49
Dizziness (excluding vertigo)	16	12	14	14
Memory impairment	5	4	6	5
Resistance Mechanism Disorders
Overall	10	6	12	10
Psychiatric
Irritability/Anxiety/Nervousness	19	22	33	38
Insomnia	19	23	30	37
Depression	18	19	20	28
Concentration impairment	8	10	10	13
Mood alteration	3	2	5	6
Respiratory, Thoracic and Mediastinal
Dyspnea	4	2	13	14
Cough	4	3	10	7
Dyspnea exertional	<1	<1	4	7
Skin and Subcutaneous Tissue
Alopecia	23	30	28	33
Pruritus	12	8	19	18
Dermatitis	8	3	16	13
Dry skin	4	3	10	13
Rash	5	4	8	5
Sweating increased	6	7	6	5
Eczema	1	1	5	4
Visual Disorders
Vision blurred	4	2	5	2

Pediatric Subjects

In a clinical trial with 114 pediatric subjects (5 to 17 years of age) treated with Pegasys alone or in combination with COPEGUS, dose modifications were required in approximately one-third of subjects, most commonly for neutropenia and anemia. In general, the safety profile observed in pediatric subjects was similar to that seen in adults. In the pediatric study, the most prevalent adverse events in subjects treated with combination therapy for up to 48 weeks with Pegasys and COPEGUS were influenza-like illness (91%), upper respiratory tract infection (60%), headache (64%), gastrointestinal disorder (56%), skin disorder (47%), and injection-site reaction (45%). Seven subjects receiving combination Pegasys and COPEGUS treatment for 48 weeks discontinued therapy for safety reasons (depression, psychiatric evaluation abnormal, transient blindness, retinal exudates, hyperglycemia, type 1 diabetes mellitus, and anemia). Most of the adverse events reported in the study were mild or moderate in severity. Severe adverse events were reported in 2 subjects in the Pegasys plus COPEGUS combination therapy group (hyperglycemia and cholecystectomy).

Growth inhibition was observed in pediatric subjects. During combination therapy for up to 48 weeks with Pegasys and COPEGUS, negative changes in weight for age z-score and height for age z-score after 48 weeks of therapy compared with baseline were observed [see Warnings and Precautions (5.15)].

Table 9 Percentage of Pediatric Subjects with Adverse Reactions* During First 24 Weeks of Treatment by Treatment Group (in at Least 10% of Subjects)

	Study NV17424
System Organ Class	Pegasys 180 mcg/1.73 m2 × BSA + COPEGUS 15 mg/kg (N=55)	Pegasys 180 mcg/1.73 m2 × BSA + Placebo† (N=59)
	%	%
* Displayed adverse drug reactions include all grades of reported adverse clinical events considered possibly, probably, or definitely related to study drug. † Subjects in the Pegasys plus placebo arm who did not achieve undetectable viral load at week 24 switched to combination treatment thereafter. Therefore, only the first 24 weeks are presented for the comparison of combination therapy with monotherapy.
General disorders and administration site conditions
Influenza like illness	91	81
Injection site reaction	44	42
Fatigue	25	20
Irritability	24	14
Gastrointestinal disorders
Gastrointestinal disorder	49	44
Nervous system disorders
Headache	51	39
Skin and subcutaneous tissue disorders
Rash	15	10
Pruritus	11	12
Musculoskeletal, connective tissue and bone disorders
Musculoskeletal pain	35	29
Psychiatric disorders
Insomnia	9	12
Metabolism and nutrition disorders
Decreased appetite	11	14

In pediatric subjects randomized to combination therapy, the incidence of most adverse reactions were similar for the entire treatment period (up to 48 weeks plus 24 weeks follow-up) in comparison to the first 24 weeks, and increased only slightly for headache, gastrointestinal disorder, irritability and rash. The majority of adverse reactions occurred in the first 24 weeks of treatment.

CHC with HIV Coinfection (Adults)

The adverse reaction profile of coinfected subjects treated with Pegasys/COPEGUS in Study 6 was generally similar to that shown for monoinfected subjects in Study 4 (Table 8). Events occurring more frequently in coinfected subjects were neutropenia (40%), anemia (14%), thrombocytopenia (8%), weight decrease (16%), and mood alteration (9%).

Chronic Hepatitis B

In clinical trials of 48 week treatment duration, the adverse reaction profile of Pegasys in chronic hepatitis B was similar to that seen in CHC Pegasys monotherapy use, except for exacerbations of hepatitis [see Warnings and Precautions (5.9)]. Six percent of Pegasys treated subjects in the hepatitis B studies experienced one or more serious adverse reactions.

The most common or important serious adverse reactions, all of which occurred at a frequency of less than or equal to 1%, in the hepatitis B studies were infections (sepsis, appendicitis, tuberculosis, influenza), hepatitis B flares, and thrombotic thrombocytopenic purpura.

One serious adverse reaction of anaphylactic shock occurred in a dose ranging study of 191 subjects in a subject taking a higher than the approved dose of Pegasys.

The most commonly observed adverse reactions in the Pegasys and lamivudine groups, respectively, were pyrexia (54% vs. 4%), headache (27% vs. 9%), fatigue (24% vs. 10%), myalgia (26% vs. 4%), alopecia (18% vs. 2%), and anorexia (16% vs. 3%).

Overall 5% of hepatitis B subjects discontinued Pegasys therapy and 40% of subjects required modification of Pegasys dose. The most common reason for dose modification in subjects receiving Pegasys therapy was for laboratory abnormalities including neutropenia (20%), thrombocytopenia (13%), and ALT elevation (11%).

Laboratory Values

Adult Patients

The laboratory test values observed in the hepatitis B trials (except where noted below) were similar to those seen in the Pegasys monotherapy CHC trials.

Neutrophils

In the hepatitis C studies, decreases in neutrophil count below normal were observed in 95% of all subjects treated with Pegasys either alone or in combination with COPEGUS. Severe potentially life-threatening neutropenia (ANC less than 500 cells/mm3) occurred in 5% of CHC subjects and 12% of CHC/HIV subjects receiving Pegasys either alone or in combination with COPEGUS. Modification of Pegasys dose for neutropenia occurred in 17% of subjects receiving Pegasys monotherapy and 22% of subjects receiving Pegasys/COPEGUS combination therapy. In the CHC/HIV subjects 27% required modification of interferon dosage for neutropenia. Two percent of subjects with CHC and 10% of subjects with CHC/HIV required permanent reductions of Pegasys dosage and less than 1% required permanent discontinuation. Median neutrophil counts return to pre-treatment levels 4 weeks after cessation of therapy [see Dosage and Administration (2.5)].

Lymphocytes

Decreases in lymphocyte count are induced by interferon alpha therapy. Pegasys plus COPEGUS combination therapy induced decreases in median total lymphocyte counts (56% in CHC and 40% in CHC/HIV, with median decrease of 1170 cells/mm3 in CHC and 800 cells/mm3 in CHC/HIV). In the hepatitis C studies, lymphopenia was observed during both monotherapy (81%) and combination therapy with Pegasys and COPEGUS (91%). Severe lymphopenia (less than 500 cells/mm3) occurred in approximately 5% of all monotherapy subjects and 14% of all combination Pegasys and COPEGUS therapy recipients. Dose adjustments were not required by protocol. The clinical significance of the lymphopenia is not known.

In CHC with HIV coinfection, CD4 counts decreased by 29% from baseline (median decrease of 137 cells/mm3) and CD8 counts decreased by 44% from baseline (median decrease of 389 cells/mm3) in the Pegasys plus COPEGUS combination therapy arm. Median lymphocyte CD4 and CD8 counts return to pre-treatment levels after 4 to 12 weeks of the cessation of therapy. CD4% did not decrease during treatment.

Platelets

In the hepatitis C studies, platelet counts decreased in 52% of CHC subjects and 51% of CHC/HIV subjects treated with Pegasys alone (respectively median decrease of 41% and 35% from baseline), and in 33% of CHC subjects and 47% of CHC/HIV subjects receiving combination therapy with COPEGUS (median decrease of 30% from baseline). Moderate to severe thrombocytopenia (less than 50,000 cells/mm3) was observed in 4% of CHC and 8% of CHC/HIV subjects. Median platelet counts return to pre-treatment levels 4 weeks after the cessation of therapy.

Hemoglobin

In the hepatitis C studies, the hemoglobin concentration decreased below 12 g/dL in 17% (median Hgb reduction of 2.2 g/dL) of monotherapy and 52% (median Hgb reduction of 3.7 g/dL) of combination therapy subjects. Severe anemia (Hgb less than 10 g/dL) was encountered in 13% of all subjects receiving combination therapy and in 2% of CHC subjects and 8% of CHC/HIV subjects receiving Pegasys monotherapy. Dose modification for anemia in COPEGUS recipients treated for 48 weeks occurred in 22% of CHC subjects and 16% of CHC/HIV subjects [see Dosage and Administration (2.6)].

Triglycerides

Triglyceride levels are elevated in subjects receiving alfa interferon therapy and were elevated in the majority of subjects participating in clinical studies receiving either Pegasys alone or in combination with COPEGUS. Random levels greater than or equal to 400 mg/dL were observed in about 20% of CHC subjects. Severe elevations of triglycerides (greater than 1000 mg/dL) occurred in 2% of CHC monoinfected subjects.

In HCV/HIV coinfected subjects, fasting levels greater than or equal to 400 mg/dL were observed in up to 36% of subjects receiving either Pegasys alone or in combination with COPEGUS. Severe elevations of triglycerides (greater than 1000 mg/dL) occurred in 7% of coinfected subjects.

ALT Elevations

Chronic Hepatitis C

One percent of subjects in the hepatitis C trials experienced marked elevations (5- to 10-fold above the upper limit of normal) in ALT levels during treatment and follow-up. These transaminase elevations were on occasion associated with hyperbilirubinemia and were managed by dose reduction or discontinuation of study treatment. Liver function test abnormalities were generally transient. One case was attributed to autoimmune hepatitis, which persisted beyond study medication discontinuation [see Dosage and Administration (2.5)].

Chronic Hepatitis B

Transient ALT elevations are common during hepatitis B therapy with Pegasys. Twenty-five percent and 27% of subjects experienced elevations of 5 to 10 × ULN and 12% and 18% had elevations of greater than 10 × ULN during treatment of HBeAg negative and HBeAg positive disease, respectively. Flares have been accompanied by elevations of total bilirubin and alkaline phosphatase and less commonly with prolongation of PT and reduced albumin levels. Eleven percent of subjects had dose modifications due to ALT flares and less than 1% of subjects were withdrawn from treatment [see Warnings and Precautions (5.9) and Dosage and Administration (2.5)].

ALT flares of 5 to 10 × ULN occurred in 13% and 16% of subjects, while ALT flares of greater than 10 × ULN occurred in 7% and 12% of subjects in HBeAg negative and HBeAg positive disease, respectively, after discontinuation of Pegasys therapy.

Thyroid Function

Pegasys alone or in combination with COPEGUS was associated with the development of abnormalities in thyroid laboratory values, some with associated clinical manifestations. In the hepatitis C studies, hypothyroidism or hyperthyroidism requiring treatment, dose modification or discontinuation occurred in 4% and 1% of Pegasys treated subjects and 4% and 2% of Pegasys and COPEGUS treated subjects, respectively. Approximately half of the subjects, who developed thyroid abnormalities during Pegasys treatment, still had abnormalities during the follow-up period [see Warnings and Precautions (5.6)].

Pediatric Patients

Decreases in hemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment [see Dosage and Administration (2.7)]. Most laboratory abnormalities noted during the clinical trial returned to baseline levels shortly after completion of treatment.

Table 10 Selected Hematologic Abnormalities During First 24 Weeks of Treatment by Treatment Group in Previously Untreated Pediatric Subjects

Laboratory Parameter	Pegasys 180 mcg/1.73 m2 × BSA + COPEGUS 15 mg/kg (N=55)	Pegasys 180 mcg/1.73 m2 × BSA + Placebo* (N=59)
* Subjects in the Pegasys plus placebo arm who did not achieve undetectable viral load at week 24 switched to combination treatment thereafter. Therefore, only the first 24 weeks are presented for the comparison of combination therapy with monotherapy.
Neutrophils (cells/mm3)
1,000 - <1,500	31%	39%
750 - <1,000	27%	17%
500 - <750	25%	15%
<500	7%	5%
Platelets (cells/mm3)
75,000 - <100,000	4%	2%
50,000 - <75,000	0%	2%
< 50,000	0%	0%
Hemoglobin (g/dL)
8.5-<10	7%	3%
<8.5	0%	0%

In patients randomized to combination therapy, the incidence of abnormalities during the entire treatment phase (up to 48 weeks plus 24 weeks follow-up) in comparison to the first 24 weeks increased slightly for neutrophils between 500 and 1,000 cells/mm³ and hemoglobin values between 8.5 and 10 g/dL. The majority of hematologic abnormalities occurred in the first 24 weeks of treatment.

Immunogenicity

Chronic Hepatitis C

Nine percent (71/834) of subjects treated with Pegasys with or without COPEGUS developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. Three percent of subjects (25/835) receiving Pegasys with or without COPEGUS, developed low-titer neutralizing antibodies (using an assay with a sensitivity of 100 INU/mL).

Chronic Hepatitis B

Twenty-nine percent (42/143) of hepatitis B subjects treated with Pegasys for 24 weeks developed binding antibodies to interferon alfa-2a, as assessed by an ELISA assay. Thirteen percent of subjects (19/143) receiving Pegasys developed low-titer neutralizing antibodies (using an assay with a sensitivity of 100 INU/mL).

The clinical and pathological significance of the appearance of serum neutralizing antibodies is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The percentage of subjects whose test results were considered positive for antibodies is highly dependent on the sensitivity and specificity of the assays.

Additionally, the observed incidence of antibody positivity in these assays may be influenced by several factors including sample timing and handling, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Pegasys with the incidence of antibodies to other products may be misleading.

Postmarketing Experience

The following adverse reactions have been identified and reported during post-approval use of Pegasys therapy. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: pure red cell aplasia

Ear and labyrinth disorders: hearing impairment, hearing loss

Immune system disorders: Liver graft rejection and renal graft rejection [see Warnings and Precautions (5.9) and Use in Specific Populations (8.8)]

Metabolism and nutrition disorders: dehydration

Skin and subcutaneous tissue disorders: serious skin reactions

Neurological: seizures

Top

Side Effects by Body System - for Healthcare Professionals

General

During hepatitis C studies, one or more serious side effects were reported in 10% of chronic hepatitis C (CHC) patients and 19% of CHC patients coinfected with HIV. The most common serious side effect was bacterial infection, including sepsis, osteomyelitis, endocarditis, pyelonephritis, and pneumonia (3% CHC, 5% CHC/HIV). Other serious side effects have included suicide, suicidal ideation, psychosis, aggression, anxiety, drug abuse and drug overdose, angina, hepatic dysfunction, fatty liver, cholangitis, arrhythmia, diabetes mellitus, autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis), peripheral neuropathy, aplastic anemia, peptic ulcer, gastrointestinal bleeding, pancreatitis, colitis, corneal ulcer, pulmonary embolism, coma, myositis, cerebral hemorrhage, thrombotic thrombocytopenic purpura, psychotic disorder, and hallucination in less than 1% of patients.

The most common side effects have included psychiatric reactions, (including depression, insomnia, irritability, and anxiety), flu-like symptoms (such as fatigue, pyrexia, myalgia, headache, rigors), anorexia, nausea and vomiting, diarrhea, arthralgias, injection site reactions, alopecia, and pruritus. Psychiatric, flu-like syndrome, dermatologic, and gastrointestinal disorders and laboratory abnormalities (thrombocytopenia, neutropenia, and anemia) were the most common reasons for discontinuation of therapy.

Immunologic

Immunologic side effects have included bacterial infections (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia), autoimmune phenomena (e.g., hyperthyroidism, hypothyroidism, sarcoidosis, systemic lupus erythematosus, rheumatoid arthritis), and the development of binding antibodies to peginterferon alfa-2a. Alpha interferons have been associated with the development or exacerbation of autoimmune disorders, including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. The most common or important serious side effects reported during hepatitis B studies have included infections (sepsis, appendicitis, tuberculosis, influenza). Liver graft rejection and renal graft rejection have been reported during postmarketing experience with peginterferon alfa-2a alone or in combination with ribavirin.

Psychiatric

Psychiatric side effects are among the most common reasons given for discontinuation of therapy.

Psychiatric side effects have included irritability/anxiety/nervousness (19% monotherapy, 33% combination therapy), depression (18% monotherapy, 20% combination therapy), concentration impairment (8% monotherapy, 10% combination therapy), and mood alteration (3% monotherapy, 5% combination therapy). Suicidal ideation, suicide, psychosis, aggression, psychotic disorder, and relapse of drug abuse and drug overdose have been reported. Impairment of desire and the potential to affect sexual satisfaction have been reported with peginterferon alfa-2a plus ribavirin in male patients.

Hematologic

Laboratory abnormalities (thrombocytopenia, neutropenia, and anemia) are among the most common reasons given for discontinuation of therapy.

Hematologic side effects have included neutropenia (21% monotherapy, 27% combination therapy), thrombocytopenia (5% monotherapy, 5% combination therapy), lymphopenia (3% monotherapy, 14% combination therapy), anemia (2% monotherapy, 11% combination therapy), aplastic anemia, thrombotic thrombocytopenic purpura, and cerebral hemorrhage. Neutropenia (40%), anemia (14%), and thrombocytopenia (8%) have been reported during treatment with peginterferon alfa-2a plus ribavirin in CHC patients coinfected with HIV. The most common or important serious side effects reported during hepatitis B studies have included thrombotic thrombocytopenic purpura. Pure red cell aplasia has been reported during postmarketing experience with peginterferon alfa-2a alone or in combination with ribavirin.

Other

Other side effects commonly reported have included fever and chills. Flu-like signs and symptoms have been reported and have included fatigue/asthenia (56% monotherapy, 65% combination therapy), pyrexia (37% to 54% monotherapy, 41% combination therapy), rigors (35% monotherapy, 25% combination therapy), and pain (11% monotherapy, 10% combination therapy). Anorexia (16% to 17% monotherapy, 24% combination therapy) and overall resistance mechanism disorders (10% monotherapy, 12% combination therapy) have been reported. Fatigue has been reported in 24% of patients during hepatitis B studies. Sarcoidosis has been reported in a 65-year-old man at the seventh month of therapy. Most of the symptoms improved over the next three months following discontinuation of therapy.

Gastrointestinal

Gastrointestinal side effects are among the most common reasons given for discontinuation of therapy.

Gastrointestinal side effects have included nausea and vomiting (24% monotherapy, 25% combination therapy), diarrhea (16% monotherapy, 11% combination therapy), abdominal pain (15% monotherapy, 8% combination therapy), dry mouth (6% monotherapy, 4% combination therapy), dyspepsia (less than 1% monotherapy, 6% combination therapy), peptic ulcer, gastrointestinal bleeding, pancreatitis, and colitis.

Nervous system

Nervous system side effects have included headache (27% to 54% monotherapy, 43% combination therapy), insomnia (19% monotherapy, 30% combination therapy), dizziness (excluding vertigo; 16% monotherapy, 14% combination therapy), concentration impairment (8%), memory impairment (5% monotherapy, 5% combination therapy), peripheral neuropathy, hallucination, and coma. At least one case of chorea and akathisia has been reported. Seizures, hearing impairment, and hearing loss have been reported during postmarketing experience.

A 40-year-old male coinfected with hepatitis C virus and HIV experienced chorea and akathisia coincident with peginterferon alfa-2a therapy. He was administered subcutaneous peginterferon alfa-2a 180 mcg weekly and oral ribavirin 1 g daily. At week 20 of therapy, the patient presented to the clinic complaining of irritability, difficulty in sleeping and prominent choreiform involuntary movements with myoclonic activity of the upper and lower extremities. He was diagnosed with chorea and akathisia. He was treated with ropinirole, propranolol, and clonazepam. Peginterferon alfa-2a and ribavirin were discontinued with complete resolution of symptoms after 5 days.

Dermatologic

Dermatologic side effects are among the most common reasons given for discontinuation of therapy.

Dermatologic side effects have included alopecia (18% to 23% monotherapy, 28% combination therapy), pruritus (12% monotherapy, 19% combination therapy), dermatitis (8% monotherapy, 16% combination therapy), increased sweating (6% monotherapy, 6% combination therapy), rash (5% monotherapy, 8% combination therapy), dry skin (4% monotherapy, 10% combination therapy), and eczema (1% monotherapy, 5% combination therapy). Skin disorders associated with combination therapy have included lichenoid eruptions and maculopapular rashes. At least one case of drug-induced Sweet's syndrome has been reported. Serious skin reactions have been reported during postmarketing experience.

Hepatic

Hepatic side effects have included elevated ALT (occasionally associated with hyperbilirubinemia), hepatic dysfunction, fatty liver, cholangitis, and exacerbations of hepatitis. Hepatic decompensation has been reported in 2% of CHC patients coinfected with HIV. The most common or important serious side effects reported during hepatitis B studies have included hepatitis B flares.

Cardiovascular

Cardiovascular side effects have included angina, arrhythmia, and endocarditis.

Metabolic

Elevated triglyceride levels have been reported in patients receiving alfa interferons, including peginterferon alfa-2a.

Metabolic side effects have included weight decrease (4% monotherapy, 10% combination therapy), elevated triglycerides, and diabetes mellitus. Dehydration has been reported during postmarketing experience.

Ocular

Ocular side effects have included blurred vision (4% monotherapy, 5% combination therapy) and corneal ulcers. Serous retinal detachment has been reported during postmarketing experience.

Respiratory

Respiratory side effects have included dyspnea (4% monotherapy, 13% combination therapy), cough (4% monotherapy, 10% combination therapy), and exertional dyspnea (less than 1% monotherapy, 4% combination therapy). Pneumonia, interstitial pneumonitis, and pulmonary embolism have been reported.

Endocrine

Endocrine side effects have included hypothyroidism (3% monotherapy, 4% combination therapy) and hyperthyroidism.

Hypersensitivity

Hypersensitivity side effects have included anaphylactic shock during hepatitis B studies.

Musculoskeletal

Musculoskeletal side effects have included myalgia (26% to 37% monotherapy, 40% combination therapy), arthralgia (28% monotherapy, 22% combination therapy), back pain (9% monotherapy, 5% combination therapy), and myositis.

Genitourinary

Genitourinary side effects associated with peginterferon alfa-2a plus ribavirin have included sexual dysfunction in male patients.

Local

Local side effects have included injection site reactions (22% monotherapy, 23% combination therapy). Skin disorders associated with combination therapy have included cutaneous necrosis at peginterferon alfa-2a injection sites. Hyperpigmentation around/over the injection sites has been reported.

Top

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.